At present, there are no specific antiviral drugs or vaccine against COVID-19 disease for potential therapy on humans. It will be worthwhile testing SARS-CoV-2 positive patients with cancer with new molecules i.e. resveretrol-copper and sodium-copper-chlorophyllin which may provide a solution to treat the pathology of COVID-19 with its possible mechanism of action. Research has shown that cfCh released from dying host cells following microbial infection leads to bystander host cell apoptosis and inflammation which is perpetuated in a vicious cycle. It can be broken by administration of R-Cu, which inactivates cfCh released from dying cells leading to amelioration of sepsis which is the end stage of COVID-19 as well as it degrades the SARS-CoV2 RNA through which it may show amelioration in viral load and clinical symptoms which may likely to show improvement in clinical condition. The objectives of this study are to assess whether resveretrol-copper and/or sodium-copper-chlorophyllin will reduce the virological load and reduce 28-day mortality in asymptomatic or mildly symptomatic COVID-19 cancer patients. This study will be carried out in 300 SARS-CoV positive cancer patients randomly assigned in 1:1:1 ratio to resveratrol-copper + standard treatment (Arm 1), sodium copper chlorophyllin + standard treatment (Arm 2) or standard treatment alone (Arm 3). The proportion of ‘Failures’ (persistence of viral load at day 10 or clinical deterioration on or before day 10) will be compared between Arm 1 and Arm 3 & between Arm 2 and Arm 3, using chi-square test and the odds ratio for ‘Failure’ will be computed in the 2 comparisons, with their respective 95% CI. The proportion of deaths (28 days mortality) will be compared between Arm 1 and Arm 2 & between Arm 2 and Arm 3, by chi-square tests and odds ratio for deaths (with their 95% CI) calculated for the 2 comparisons.